Related Experiment Video
Updated: Dec 2, 2025
An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
Published on: July 20, 2014
Pseudolaric Acid B Inhibits Proliferation, Invasion, and Angiogenesis in Esophageal Squamous Cell Carcinoma Through
Zhe Yin1, Huarong Cai1, Zhiqiang Wang1
1Department of Thoracic Surgery, Chongqing University Cancer Hospital, Chongqing 400030, China.
Background:
Esophageal squamous cell carcinoma (ESCC) is a common malignant tumor of the digestive system. Studies have shown that pseudolaric acid B (PAB) has several pharmacological effects like anti-microtubule, anti-angiogenesis, and antitumor functions, while the effect and mechanism of PAB on esophageal cancer are still unclear. This study was designed to investigate the effects of PAB on ESCC.
Methods:
To study the effects of PAB on the biological function through a series of in vitro and in vivo experiments.
Results:
The results revealed that PAB inhibited the proliferation, invasion, and migration, but promoted the apoptosis of ESCC. Moreover, PAB restrained the growth of cancer cells in vivo and inhibited the angiogenesis of HUVEC in mice with ESCC. CD147 expression was increased in the esophageal squamous cell lines, and interference with CD147 hindered the proliferation, invasion, and migration of ESCC cells, and inhibited the growth and angiogenesis of the esophageal squamous cell line. PAB reduced the expression of CD147 in vivo and in vitro. The expression of MMP2, 3, and 9 was increased after overexpression of CD147, which provided the opportunity to reverse the role of PAB in inhibiting proliferation, invasion, migration, and angiogenesis of ESCC.
Discussion:
The results revealed that PAB inhibited the proliferation, invasion, migration, and angiogenesis of ESCC in vitro and in vivo by CD147. PAB is a promising monomer for therapy of ESCC, providing references for future research on ESCC treatment.
Insights
Pseudolaric acid B (PAB) effectively inhibits esophageal squamous cell carcinoma (ESCC) progression by targeting CD147. This natural compound shows promise for ESCC therapy by reducing cell proliferation, invasion, migration, and angiogenesis.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Esophageal squamous cell carcinoma (ESCC) is a prevalent digestive system malignancy.
- Pseudolaric acid B (PAB) exhibits known anti-microtubule, anti-angiogenesis, and antitumor properties.
- The specific effects and mechanisms of PAB on ESCC remain largely unexplored.
Purpose of the Study:
- To investigate the therapeutic effects of PAB on esophageal squamous cell carcinoma (ESCC).
- To elucidate the underlying molecular mechanisms of PAB's action in ESCC.
Main Methods:
- Conducted a series of in vitro and in vivo experiments to assess PAB's biological effects on ESCC.
- Analyzed cell proliferation, invasion, migration, and apoptosis.
- Investigated the role of CD147 and matrix metalloproteinases (MMPs) in PAB's mechanism of action.
Main Results:
- PAB significantly inhibited ESCC cell proliferation, invasion, and migration while promoting apoptosis in vitro.
- PAB suppressed tumor growth and angiogenesis in vivo.
- PAB reduced CD147 expression, which was found to be upregulated in ESCC cells and associated with increased MMP2, 3, and 9 expression.
- Interference with CD147 mimicked PAB's inhibitory effects on ESCC progression and angiogenesis.
Conclusions:
- PAB exerts its anti-cancer effects on ESCC by downregulating CD147 expression, thereby inhibiting proliferation, invasion, migration, and angiogenesis.
- PAB represents a promising therapeutic agent for ESCC, warranting further investigation for clinical application.
Related Concept Videos
02:34Inhibition of Cdk Activity
01:24Regulation of Angiogenesis and Blood Supply